English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech (Sci&Research)
中国生物制药旗下北京泰德与Graviton达成海外授权合作协议
Feb 25, 2021 17:33 HKT
中國生物製藥旗下北京泰德與Graviton達成海外授權合作協議
Feb 25, 2021 17:32 HKT
Maculus Therapeutix欢迎Privity,为新型药物输送平台筹集资金
Feb 24, 2021 07:00 HKT
Maculus Therapeutix歡迎Privity,為新型藥物輸送平台籌集資金
Feb 24, 2021 07:00 HKT
Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform
Feb 19, 2021 07:00 HKT
Suntrap Discovered 'LeSoleil' for COVID-19 and the Epidemic
Feb 14, 2021 20:00 HKT
Cofttek, China's Largest Manufacturer of PEA, Draws Attention of Investors
Feb 14, 2021 01:00 HKT
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
Feb 12, 2021 13:00 HKT
APOLLOMICS(冠科美博)在中國和南非引進一款靶向主動免疫檢查點控制劑重組疫苗
Feb 12, 2021 13:00 HKT
APOLLOMICS(冠科美博)在中国和南非引进一款靶向主动免疫检查点控制剂重组疫苗
Feb 12, 2021 13:00 HKT
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial
Feb 11, 2021 21:00 HKT
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
Feb 11, 2021 11:00 HKT
APOLLOMICS(冠科美博)從ITERION THERAPEUTICS引進TEGAVIVINT
Feb 11, 2021 11:00 HKT
APOLLOMICS(冠科美博)从ITERION THERAPEUTICS引进TEGAVIVINT
Feb 11, 2021 11:00 HKT
APOLLOMICS(冠科美博)从EDISON ONCOLOGY引进一款创新实体瘤酪氨酸蛋白激酶抑制剂
Feb 10, 2021 10:12 HKT
APOLLOMICS(冠科美博)從EDISON ONCOLOGY引進一款創新實體瘤酪氨酸蛋白激酶抑制劑
Feb 10, 2021 10:11 HKT
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
Feb 10, 2021 10:10 HKT
基因检测行业的未来明珠获资本巨头鼎力相助 诺辉健康潜力十足
Feb 08, 2021 16:06 HKT
基因檢測行業的未來明珠獲資本巨頭鼎力相助 諾輝健康潛力十足
Feb 08, 2021 16:05 HKT
诺辉健康商业前景可观 长期投资价值极佳
Feb 05, 2021 16:01 HKT
Next >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: